Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
91. |
ECCT/21/07/06 | GBT132_Inclacumab-Ps 3 Trial A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Fredrick Asirwa Chite 2. Videlis N Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Strathmore University Medical Centre (Nairobi City county) |
09-11-2021 |
View |
92. |
ECCT/21/07/05 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Dr Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. KEMRI Walter Reed Project (Kericho county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
09-11-2021 |
View |
93. |
ECCT/21/06/13 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) 3. Aga khan University Hospital (Nairobi City county) |
18-11-2021 |
View |
94. |
ECCT/21/08/01 | CARES Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa. |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya 1. AMPATH Eldoret (Uasin Gishu county) 2. Aghakhan University (Nairobi City county) 3. Kericho KEMRI WRP CRC site (Kericho county) |
30-11-2021 |
View |
95. |
ECCT/21/06/14 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Kisumu Clinical Research Site (Kisumu county) |
13-12-2021 |
View |
96. |
ECCT/21/11/04 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Fredrick Sirwa Chite 2. Prof Jessie N Githanga 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
21-12-2021 |
View |
97. |
ECCT/21/11/01 | VAT 00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Walter Godfrey Jaoko Site(s) in Kenya 1. Kenya Medical Research Institute (Kisumu county) 2. KEMRI/Walter Reed Project Research Center (Kericho county) 3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county) 4. KEMRI CMR (Kisumu county) 5. Kenya Medical Research Institute (Nairobi City county) 6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 7. Moi University Clinical Research Centre (Uasin Gishu county) 8. Aga Khan University Hospital (Nairobi City county) 9. KEMRI CCR-Butere County Hospital Site (Kakamega county) 10. Ganjoni Clinic (Mombasa county) |
15-01-2022 |
View |
98. |
ECCT/21/11/08 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Videlis N Nduba 2. Prof. Jessie N Githanga 3. Fredrick Sirwa Chite 4. Bernhards Ragama Ogutu Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) 3. Gertrude’s Children’s Hospital. (Nairobi City county) 4. Strathmore University Medical Centre (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
02-02-2022 |
View |
99. |
ECCT/22/01/06 | AIKILI Technology Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology |
Principal Investigator(s) 1. Laura Kelley Kelley Site(s) in Kenya Aga Khan University Hospital, Nairobi. |
21-03-2022 |
View |
100. |
ECCT/21/12/07 | GBT 132- Inclacumab Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Videlis N Nduba 3. Fredrick Asirwa Chite Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) |
21-03-2022 |
View |